1. Home
  2. NBTB vs ZLAB Comparison

NBTB vs ZLAB Comparison

Compare NBTB & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NBT Bancorp Inc.

NBTB

NBT Bancorp Inc.

N/A

Current Price

$50.61

Market Cap

2.7B

Sector

Finance

ML Signal

N/A

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

N/A

Current Price

$21.06

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NBTB
ZLAB
Founded
1856
2013
Country
United States
China
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.6B
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
NBTB
ZLAB
Price
$50.61
$21.06
Analyst Decision
Hold
Strong Buy
Analyst Count
7
12
Target Price
★ $57.17
$34.21
AVG Volume (30 Days)
237.5K
★ 1.1M
Earning Date
10-27-2026
11-05-2026
Dividend Yield
★ 3.15%
N/A
EPS Growth
12.12
★ 38.46
EPS
★ 3.10
N/A
Revenue
$182,952,000.00
★ $460,156,000.00
Revenue This Year
$9.31
N/A
Revenue Next Year
$5.48
$22.47
P/E Ratio
$16.37
★ N/A
Revenue Growth
10.40
★ 15.33
52 Week Low
$40.13
$15.96
52 Week High
$55.35
$29.02

Technical Indicators

Market Signals
Indicator
NBTB
ZLAB
Relative Strength Index (RSI) 39.79 36.38
Support Level $49.89 $17.35
Resistance Level $51.09 $26.64
Average True Range (ATR) 1.04 1.37
MACD -0.33 -0.33
Stochastic Oscillator 9.16 10.89

Price Performance

Historical Comparison
NBTB
ZLAB

About NBTB NBT Bancorp Inc.

NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

Share on Social Networks: